Assessment of DNA damage by the DNA comet assay in comorbid patients with cardiological and endocrinological profiles

   Relevance. The incidence of cardiovascular diseases and type 2 diabetes mellitus is increasing worldwide, and the commonality and interrelation of their pathogenetic mechanisms determine the frequent development of comorbidity associated with high mortality rates, disability, and lower quality of life. The development of the most common chronic non-communicable diseases is based on oxidative stress, under which DNA damage occurs. In the last two decades, the relationship between DNA damage and the development and progression of metabolic disorders, cardiovascular lesions, and the possibility of using DNA damage as a biomarker have been actively studied.

   Objective. Based on the analysis of currently available studies, to establish a relationship between the occurrence and accumulation of DNA damage with the development of comorbid pathology, including CVD and type 2 diabetes.

   Methods. An analysis of Russian and foreign literary sources was conducted in databases such as PubMed, Google Scholar, RSCI and eLibrary. It was decided to review studies assessing the association of DNA damage with MS, T2DM and CVD, and, based on the results obtained, to draw conclusions about the possible impact of comorbidity for these conditions on DNA structure.

   Results. The results of the studies allow us to conclude that the development and progression of MS and associated T2DM and CVD are associated with the accumulation of high levels of DNA damage. It is important for comorbid patients with coronary heart disease and hypertension to consider the possible genotoxic effect of the prescribed drug therapy.

   Conclusion. The studies presented in this review demonstrate a strong correlation of DNA damage determined by the DNA comet assay with metabolic disorders and markers of oxidative stress. The determination of DNA damage has prognostic value for comorbid patients and is a valuable biomarker that facilitates the early detection and treatment of combined cardiovascular and endocrine pathology.

1. Chandrasekaran P, Weiskirchen R. The Role of Obesity in Type 2 Diabetes Mellitus-An Overview. Int J Mol Sci. 2024 Feb 4;25(3):1882. doi: 10.3390/ijms25031882.

2. Kytikova OY, Antonyuk MV, Kantur TA, et al. Prevalence and biomarkers in metabolic syndrome. Obesity and metabolism. 2021;18(3):302-312. (In Russ.) doi: 10.14341/omet12704.

3. Zheleznyakova AV, Vikulova OK, Serkov AA, et al. Dynamic monitoring of cardiovascular diseases in patients with diabetes mellitus according to mobile medical center (Diamodule) in the regions of Russia. Consilium Medicum. 2020;22(10):39-44. (In Russ.) doi: 10.26442/20751753.2020.10.200323.

4. Kalashnikov VY, Michurova MS. Atherosclerotic Cardiovascular Diseases and Type 2 Diabetes Mellitus – new Developments in the Treatment. Kardiologiia. 2021;61(1):78-86. (In Russ.) doi: 10.18087/cardio.2021.1.n1148.

5. Drapkina OM, Kontsevaya AV, Kalinina AM, et al. Comorbidity of patients with noncommunicable diseases in general practice. Eurasian guidelines. Cardiovascular Therapy and Prevention. 2024;23(3):3996. (In Russ.) doi: 10.15829/1728-8800-2024-3996. EDN AVZLPJ.

6. Wong ND, Sattar N. Cardiovascular risk in diabetes mellitus: epidemiology, assessment and prevention. Nat Rev Cardiol. 2023 Oct;20(10):685-695. doi: 10.1038/s41569-023-00877-z.

7. Fleming AM, Ding Y, Burrows CJ. Oxidative DNA damage is epigenetic by regulating gene transcription via base excision repair. Proc Natl Acad Sci U S A. 2017 Mar 7;114(10):2604-2609. doi: 10.1073/pnas.1619809114.

8. 8. Ray S, Abugable AA, Parker J, et al. A mechanism for oxidative damage repair at gene regulatory elements. Nature. 2022 Sep;609(7929):1038-1047. doi: 10.1038/s41586-022-05217-8.

9. Møller P, Azqueta A, Boutet-Robinet E, et al. Minimum Information for Reporting on the Comet Assay (MIRCA): recommendations for describing comet assay procedures and results. Nat Protoc. 2020 Dec;15(12):3817-3826. doi: 10.1038/s41596-020-0398-1.

10. Collins A, Møller P, Gajski G, et al. Measuring DNA modifications with the comet assay: a compendium of protocols. Nat Protoc. 2023 Mar;18(3):929-989. doi: 10.1038/s41596-022-00754-y.

11. Muruzabal D, Collins A, Azqueta A. The enzyme-modified comet assay: Past, present and future. Food Chem Toxicol. 2021 Jan;147:111865. doi: 10.1016/j.fct.2020.111865.

12. Piché ME, Tchernof A, Després JP. Obesity Phenotypes, Diabetes, and Cardiovascular Diseases. Circ Res. 2020 May 22;126(11):1477-1500. doi: 10.1161/CIRCRESAHA.120.316101.

13. Demirbag R, Yilmaz R, Gur M, et al. DNA damage in metabolic syndrome and its association with antioxidative and oxidative measurements. Int J Clin Pract. 2006 Oct;60(10):1187-93. doi: 10.1111/j.1742-1241.2006.01042.x.

14. Bukhari SA, Rajoka MI, Nagra SA, Rehman ZU. Plasma homocysteine and DNA damage profiles in normal and obese subjects in the Pakistani population. Mol Biol Rep. 2010 Jan;37(1):289-95. doi: 10.1007/s11033-009-9686-0.

15. Karaman A, Aydın H, Geçkinli B, et al. DNA damage is increased in lymphocytes of patients with metabolic syndrome. Mutat Res Genet Toxicol Environ Mutagen. 2015 Apr;782:30-5. doi: 10.1016/j.mrgentox.2015.03.009.

16. Milic M, Frustaci A, Del Bufalo A, et al. DNA damage in non-communicable diseases: A clinical and epidemiological perspective. Mutat Res. 2015 Jun;776:118-27. doi: 10.1016/j.mrfmmm.2014.11.009.

17. Steven S, Frenis K, Oelze M, et al. Vascular Inflammation and Oxidative Stress: Major Triggers for Cardiovascular Disease. Oxid Med Cell Longev. 2019 Jun 23;2019:7092151. doi: 10.1155/2019/7092151.

18. Darenskaya MA, Kolesnikova LI, Kolesnikov SI. Oxidative Stress: Pathogenetic Role in Diabetes Mellitus and Its Complications and Therapeutic Approaches to Correction. Bull Exp Biol Med. 2021 May;171(2):179-189. doi: 10.1007/s10517-021-05191-7.

19. Lodovici M, Giovannelli L, Pitozzi V, et al. Oxidative DNA damage and plasma antioxidant capacity in type 2 diabetic patients with good and poor glycaemic control. Mutat Res. 2008 Feb 1;638(1-2):98-102. doi: 10.1016/j.mrfmmm.2007.09.002.

20. Palazzo RP, Bagatini PB, Schefer PB, et al. Genomic instability in patients with type 2 diabetes mellitus on hemodialysis. Rev Bras Hematol Hemoter. 2012;34(1):31-5. doi: 10.5581/1516-8484.20120011.

21. Andreassi MG, Barale R, Iozzo P, Picano E. The association of micronucleus frequency with obesity, diabetes and cardiovascular disease. Mutagenesis. 2011 Jan;26(1):77-83. doi: 10.1093/mutage/geq077.

22. Boehm BO, Möller P, Högel J, et al. Lymphocytes of type 2 diabetic women carry a high load of stable chromosomal aberrations: a novel risk factor for disease-related early death. Diabetes. 2008 Nov;57(11):2950-7. doi: 10.2337/db08-0274.

23. Szaflik JP, Rusin P, Zaleska-Zmijewska A, et al. Reactive oxygen species promote localized DNA damage in glaucoma-iris tissues of elderly patients vulnerable to diabetic injury. Mutat Res. 2010 Mar 29;697(1-2):19-23. doi: 10.1016/j.mrgentox.2010.02.003.

24. Shaito A, Aramouni K, Assaf R, et al. Oxidative Stress-Induced Endothelial Dysfunction in Cardiovascular Diseases. Front Biosci (Landmark Ed). 2022 Mar 18;27(3):105. doi: 10.31083/j.fbl2703105.

25. Madamanchi NR, Runge MS. Mitochondrial dysfunction in atherosclerosis. Circ Res. 2007 Mar 2;100(4):460-73. doi: 10.1161/01.RES.0000258450.44413.96.

26. Kliemann M, Prá D, Müller LL, et al. DNA damage in children and adolescents with cardiovascular disease risk factors. An Acad Bras Cienc. 2012 Sep;84(3):833-40. doi: 10.1590/s0001-37652012005000039.

27. Botto N, Masetti S, Petrozzi L, et al. Elevated levels of oxidative DNA damage in patients with coronary artery disease. Coron Artery Dis. 2002 Aug;13(5):269-74. doi: 10.1097/00019501-200208000-00004.

28. Demirbag R, Yilmaz R, Gur M, et al. Lymphocyte DNA damage in patients with acute coronary syndrome and its relationship with severity of acute coronary syndrome. Mutat Res. 2005 Oct 15;578(1-2):298-307. doi: 10.1016/j.mrfmmm.2005.05.005.

29. Rajesh KG, Surekha RH, Mrudula SK, Prasad Y, Sanjib KS, Prathiba N. Oxidative and nitrosative stress in association with DNA damage in coronary heart disease. Singapore Med J. 2011 Apr;52(4):283-8.

30. Møller P, Stopper H, Collins AR. Measurement of DNA damage with the comet assay in high-prevalence diseases: current status and future directions. Mutagenesis. 2020 Feb 13;35(1):5-18. doi: 10.1093/mutage/gez018.

31. Bhat MA, Gandhi G. Assessment of DNA Damage in Leukocytes of Patients With Coronary Artery Disease by Comet Assay. Int Heart J. 2017 Apr 6;58(2):271-274. doi: 10.1536/ihj.16-190.

32. Bhat MA, Gandhi G. Elevated oxidative DNA damage in patients with coronary artery disease and its association with oxidative stress biomarkers. Acta Cardiol. 2019 Apr;74(2):153-160. doi: 10.1080/00015385.2018.1475093.

33. Yildiz A, Gür M, Yilmaz R, et al. Lymphocyte DNA damage and total antioxidant status in patients with white-coat hypertension and sustained hypertension. Turk Kardiyol Dern Ars. 2008 Jun;36(4):231-8.

34. Hazukova R, Rezacova M, Pleskot M, et al. DNA damage and arterial hypertension. A systematic review and meta-analysis. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2024 Mar;168(1):15-24. doi: 10.5507/bp.2023.044.

35. Gray K, Kumar S, Figg N, et al. Effects of DNA damage in smooth muscle cells in atherosclerosis. Circ Res. 2015 Feb 27;116(5):816-26. doi: 10.1161/CIRCRESAHA.116.304921.